FDA expands use of stool test from BD Diagnostics

01/12/2009 | Forbes

The FDA has allowed BD Diagnostics, a unit of Becton, Dickinson and Co., to sell a stool test for the "rapid detection" of a toxin that can cause clostridium difficile infection. The BD GeneOhm Cdiff molecular test, which could remove the need for multiple screenings, is already approved for use in spotting methicillin-resistant Staphylococcus aureus.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations